<!DOCTYPE html>
<html lang="en">
<head>
   <meta charset="UTF-8">
   <meta http-equiv="X-UA-Compatible" content="IE=edge">
   <meta name="viewport" content="width=device-width, initial-scale=1.0">
   <link rel="stylesheet" type="text/css" href="https://cdn.jsdelivr.net/npm/daterangepicker/daterangepicker.css" />
   <link rel="stylesheet" href="../assets/css/bootstrap.min.css">
   <link rel="stylesheet" href="../assets/css/slick.css">
   <link rel="stylesheet" href="../assets/css/slick-theme.css">
   <link rel="stylesheet" href="../assets/css/style.css">
   <title>Document</title>
</head>
<body>
   
    <div class="hl-platforms">
        <div class="content-wrapper">
            <div class="hl-platforms__head">
                <h4 class="hl-whatwedo__title">Product <span>Portfolio</span></h4>
                <p class="hl-partnership__para">Hilleman is proud to have built a portfolio of advanced product candidates to meet global public health needs, particularly in low- and middle-income countries.</p>
            </div>
            <!-- innovation tile starts -->
             <div class="hl-research hl-inntile">
                 <div class="hl-research__outer">
                     <div class="hl-research__left">
                       <h4 class="hl-research__title">HillChol®</h4>
                         <p>HillChol® is Hilleman Laboratories’ flagship vaccine. It is a best-in-class oral cholera vaccine developed as a single strain, single dose liquid oral delivery. Phase III clinical trials of the vaccine have concluded and is pending approval and licensure in certain territories. As a single strain vaccine, the cost of production is significantly lower and when made available, the vaccine will have a huge positive impact in countries such as India, Bangladesh and GAVI countries where cholera is endemic.</p>
                   </div>
                   <div class="hl-research__right">
                      <img src="../assets/images/HillChol.png" alt="">
                   </div>
                </div>
              </div>
              <div class="hl-research hl-inntile hl-research--inv">
                  <div class="hl-research__outer">
                      <div class="hl-research__left">
                        <h4 class="hl-research__title">ERVEBO® (Ebola Zaire)</h4>
                          <p>ERVEBO® is an Ebola vaccine used in ring vaccination strategies in Central and West Africa to tackle recent outbreaks since 2014. In partnership with Merck Research Labs, ERVEBO® is being improved for a standard thermostability profile (4–8°C) compared to the current (-80°C). The improvements are aimed at making the vaccine more affordable, and increasing production volumes to provide wider, more equitable access.</p>
                    </div>
                    <div class="hl-research__right">
                       <img src="../assets/images/ERVEBO.png" alt="">
                    </div>
                 </div>
              </div>
             <div class="hl-research hl-inntile">
                 <div class="hl-research__outer">
                     <div class="hl-research__left">
                       <h4 class="hl-research__title">Q Fever LPS Conjugate Vaccine</h4>
                         <p>World’s first scientific demonstration on an LPS conjugate vaccine for Coxiella burnetii which causes Q Fever, an epidemic that is considered an occupational hazard among laboratory, livestock, and veterinary workers and is also considered a bioterrorism agent.</p>
                   </div>
                   <div class="hl-research__right">
                      <img src="../assets/images/Q Fever LPS Conjugate Vaccine.png" alt="">
                   </div>
                </div>
              </div>
              <div class="hl-research hl-inntile hl-research--inv">
                  <div class="hl-research__outer">
                      <div class="hl-research__left">
                        <h4 class="hl-research__title">MenACYWX</h4>
                          <p>A pentavalent meningitis vaccine which has the broadest coverage against the main circulating vaccine strains that cause infection and disease, with several granted patents in developed and developing countries.</p>
                    </div>
                    <div class="hl-research__right">
                       <img src="../assets/images/MenACYWX.png" alt="">
                    </div>
                 </div>
              </div>
             <div class="hl-research hl-inntile">
                 <div class="hl-research__outer">
                     <div class="hl-research__left">
                       <h4 class="hl-research__title">rHSA as an excipient</h4>
                         <p>An optimized high-yield yeast-based platform for an alternative cost-effective way to produce recombinant human serum albumin (rHSA) for use as an excipient in vaccines and therapeutics.</p>
                   </div>
                   <div class="hl-research__right">
                      <img src="../assets/images/rHSA as an excipient.png" alt="">
                   </div>
                </div>
              </div>
            <!-- innovation tile end -->
        </div>
    </div>

   <!-- script start -->
   <script src="../assets/js/jquery-3.5.1.slim.min.js"></script>
   <script src="../assets/js/bootstrap.bundle.min.js"></script>
   <script src="../assets/js/slick.min.js"></script>
   <script type="text/javascript" src="https://cdn.jsdelivr.net/momentjs/latest/moment.min.js"></script>
   <script type="text/javascript" src="https://cdn.jsdelivr.net/npm/daterangepicker/daterangepicker.min.js"></script>
   <script src="../assets/js/script.js"></script>
</body>
</html>
<!--  -->